An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2022
This article has no abstract
Epistemonikos ID: 9d20c0d88c6d89866b2f965c76f2c10ab1c4a084
First added on: Jan 23, 2025